MedTrace Logo

Keloid Scarring: Treatment and Pathophysiology

NCT01295099 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2023-09-18

No results posted yet for this study

Summary

To clarify the mechanisms of Keloid scar formation.

Elucidate the action and therapeutic value of 5-FU in Keloid scar treatment

Identify the genetic link with Keloid scar formation.

Quantify the psychological/social impact in keloid scarring patients

Conditions

  • Keloid Scar

Interventions

DRUG

5- fluorouracil

5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions

RADIATION

radiotherapy

after complete excision of keloid they have a single session of radiotherapy

DRUG

Triamcinolone

TAC 10mg in 1ml injected intralesional

Sponsors & Collaborators

  • Queen Mary University of London

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01295099 on ClinicalTrials.gov